Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Property And Equipment Estimated Useful Lives

The estimated useful life of the different groups of property and equipment is as follows:


Asset Classification		Estimated useful life (in years)
Leasehold improvements		shorter of useful life or remaining life of the lease
Laboratory equipment		1 - 14
Office and computer equipment		1 - 15

Schedule of Fair Value Assumptions

Accordingly, the weighted-average fair value of the options granted during the years ended December 31, 2015 and 2014 was $2.02 and $1.30, respectively based on the following assumptions:


	Years Ended December 31,
	2015	2014
Risk free interest rate	1.47%-1.89%	1.77%
Expected term	5.0 – 6.1 years	5.6 – 5.8 years
Dividend yield	—	—
Expected volatility	72.65%-75.07%	74.66%

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense was recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows:


	Years Ended December 31,
	2015		2014
Research and development	$	379,066	$	7,623
General and administrative		785,567		563,759

Total stock-based compensation	$	1,164,633	$	571,382

Schedule of Changes to Accumulated Other Comprehensive Income

Changes to accumulated other comprehensive income as of December 31, 2015 were as follows:


	Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income
Balance—December 31, 2013	$	(956,273	)	$	(956,273	)
Current period other comprehensive loss		113,176			113,176
Balance—December 31, 2014		(843,097	)		(843,097	)
Current period other comprehensive loss		(429,477	)		(429,477	)

Balance—December 31, 2015	$	(1,272,574	)	$	(1,272,574	)